Icecure Medical is trading at $2.91, down -6.28%, after second-quarter revenue missed analyst expectations despite strong year-over-year growth.
- Selling pressure continued after August 12, 2026, when results disappointed investors; the company-specific decline followed an earnings-related selloff that overshadowed commercial-installation growth and improved gross margins.
- First-half revenue rose 45% to $1.8 million, supported by system and probe sales.
- The company ended the first half with $12 million in cash and equivalents.